The distribution agreement covers the sale of AxiaLIF products in China with the exception of Hong Kong, Macau and Taiwan. TranS1’s AxiaLIF implants were granted a registration certificate by China’s State Food and Drug Administration, and the remaining instrumentation is expected to receive their respective registration in the fourth quarter of 2012.
More Articles on Orthopedic Devices:
Smith & Nephew Launches TRIGEN Low-Profile Screw
Mazor Robotics Finalizes $15M in Financing
Implantate Extends Contracts of All Board Members
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
